[
  {
    "ts": null,
    "headline": "Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today that Health Canada has issued a Notice of Compliance (NOC) for CARVYKTI® (ciltacabtagene autoleucel) for the treatment of adult patients with multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell Maturation Antigen (BCMA)-targeted therapy approved for the treatment o",
    "url": "https://finnhub.io/api/news?id=b18accd123fbcf73d1e0de114f4f4f3d32d603a22d13bfd2da92bbd9aa3b50c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732222800,
      "headline": "Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy",
      "id": 131549037,
      "image": "https://media.zenfs.com/en/cnwgroup.com/4f0d10ec490836c1ece263d8c7f19b2e",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) announced today that Health Canada has issued a Notice of Compliance (NOC) for CARVYKTI® (ciltacabtagene autoleucel) for the treatment of adult patients with multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell Maturation Antigen (BCMA)-targeted therapy approved for the treatment o",
      "url": "https://finnhub.io/api/news?id=b18accd123fbcf73d1e0de114f4f4f3d32d603a22d13bfd2da92bbd9aa3b50c2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson stock outperforms competitors on strong trading day",
    "summary": "Johnson & Johnson stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=c3222209adecd4ffc8af6dca402898777935e21b1a9fc9e33a44507e69935c8c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732206660,
      "headline": "Johnson & Johnson stock outperforms competitors on strong trading day",
      "id": 131598972,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=c3222209adecd4ffc8af6dca402898777935e21b1a9fc9e33a44507e69935c8c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock: Unexpected Developments (Rating Downgrade)",
    "summary": "Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.",
    "url": "https://finnhub.io/api/news?id=8dba672ef37d68756bf83608066d12fd631a9f63c6a8402fd2f0641c0046b39f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732206364,
      "headline": "Eli Lilly Stock: Unexpected Developments (Rating Downgrade)",
      "id": 131547530,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284860965/image_1284860965.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.",
      "url": "https://finnhub.io/api/news?id=8dba672ef37d68756bf83608066d12fd631a9f63c6a8402fd2f0641c0046b39f"
    }
  },
  {
    "ts": null,
    "headline": "Hundreds of women in UK sue Johnson & Johnson over link between talc and cancer",
    "summary": "Copyright © BusinessAMBE 2023Key takeawaysHundreds of women in the United Kingdom are taking legal action against Johnson & Johnson on suspicion of a link between talc products and cancer.The...",
    "url": "https://finnhub.io/api/news?id=30c578fdaf1e49a8df0fcb6e88a39f378d6a3bfbe7c650d8f98843047b09ab3f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732204877,
      "headline": "Hundreds of women in UK sue Johnson & Johnson over link between talc and cancer",
      "id": 131546892,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Copyright © BusinessAMBE 2023Key takeawaysHundreds of women in the United Kingdom are taking legal action against Johnson & Johnson on suspicion of a link between talc products and cancer.The...",
      "url": "https://finnhub.io/api/news?id=30c578fdaf1e49a8df0fcb6e88a39f378d6a3bfbe7c650d8f98843047b09ab3f"
    }
  },
  {
    "ts": null,
    "headline": "Franklin Income Fund Q3 2024 Commentary",
    "summary": "Franklin Income Fund underperformed its benchmark for the quarter ended September 30, 2024, while it outpaced the gain of the S&P 500 Index. Read more here.",
    "url": "https://finnhub.io/api/news?id=e728ea19283433f32430d533441155248b294fba7d9d1587616332c051759624",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732199400,
      "headline": "Franklin Income Fund Q3 2024 Commentary",
      "id": 131543395,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1360003423/image_1360003423.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Franklin Income Fund underperformed its benchmark for the quarter ended September 30, 2024, while it outpaced the gain of the S&P 500 Index. Read more here.",
      "url": "https://finnhub.io/api/news?id=e728ea19283433f32430d533441155248b294fba7d9d1587616332c051759624"
    }
  }
]